None of the information included in the document regarding HTA reform, cost-recovery changes, or new statutory price reductions guarantees anything will appear in the 2026–27 Budget. Yet it does confirm active inter-departmental planning, formal discussions and preparation for their potential inclusion.
We know they're planning something on these issues, because they told us
November 18, 2025 Latest NewsBioPharmaComment
Latest Video
New Stories
-
Pfizer’s high-stakes sprint to build momentum in century-defining market
December 11, 2025 - - Latest News -
Mayne Pharma rejects Cosette’s attempt to terminate scheme deal
December 10, 2025 - - Latest News -
TGA clears the way for LTR Pharma’s Phase 2 Study of SPONTAN
December 10, 2025 - - Australian Biotech -
OncoSil announces first UK patient treated with its pancreatic cancer treatment
December 10, 2025 - - Australian Biotech -
Health Department clarifies PBAC plan after confusion over paediatric access to biologics
December 10, 2025 - - Latest News -
If this was the plan, why wasn't it included in the response to questions last week?
December 10, 2025 - - Latest News -
Immutep strikes major licensing deal with Dr. Reddy’s to commercialise novel cancer immunotherapy
December 9, 2025 - - Australian Biotech
